Cargando…

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)

OBJECTIVE: To assess whether the combined oral contraceptive (COC) ethinylestradiol (EE) 20 μg/drospirenone 3 mg taken in a 24/4-day regimen (ie, 4-day hormone-free interval) is more effective than an EE 20 μg/desogestrel (DSG) 150 μg COC taken in a 21/7-day regimen (ie, 7-day hormone-free interval)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bitzer, Johannes, Banal-Silao, Maria Jesusa, Ahrendt, Hans-Joachim, Restrepo, Jaime, Hardtke, Marion, Wissinger-Graefenhahn, Ulrike, Trummer, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445871/ https://www.ncbi.nlm.nih.gov/pubmed/26056491 http://dx.doi.org/10.2147/IJWH.S77942

Ejemplares similares

Randomized control trial to compare effects of ultra-low dose (Ethinylestradiol 20 μg or 15 μg) with low dose (Ethinylestradiol 30 μg) hormonal pills on lipid discordance in non-obese PCOS women
por: Dasgupta, Subhankar, et al.
Publicado: (2023)

Ethinylestradiol(30μg)-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
por: Ilie, Ioana Rada, et al.
Publicado: (2012)

Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

Adherence with ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
por: Wiegratz, Inka, et al.
Publicado: (2015)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
por: Klipping, Christine, et al.
Publicado: (2012)

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg
por: Bonassi Machado, Rogerio, et al.
Publicado: (2020)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin
por: Bachmann, Gloria, et al.
Publicado: (2009)

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome
por: Mathur, Ruchi, et al.
Publicado: (2008)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Efficacy of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study
por: Strowitzki, Thomas, et al.
Publicado: (2012)

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People’s Republic of China: a comparison with international studies
por: Marr, Joachim, et al.
Publicado: (2015)

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
por: Momoeda, Mikio, et al.
Publicado: (2017)

Performance of Ceftazidime-Avibactam 30/20-μg and 10/4-μg Disks for Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
por: Han, Renru, et al.
Publicado: (2023)

Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin
por: Sun, Xianchang, et al.
Publicado: (2015)

Effect and safety of drospirenone and ethinylestradiol tablets (II) for dysmenorrhea: A systematic review and meta-analysis
por: Shi, Jinghua, et al.
Publicado: (2022)

The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg
por: Krishnan, Sheila, et al.
Publicado: (2010)

Quality of Life in Japanese Patients with Dysmenorrhea or Endometriosis-Associated Pelvic Pain Treated with Extended Regimen Ethinylestradiol/Drospirenone in a Real-World Setting: A Prospective Observational Study
por: Yoshino, Osamu, et al.
Publicado: (2022)

Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen
por: Mansour, Diana, et al.
Publicado: (2011)

Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers
por: Pena, María Ángeles, et al.
Publicado: (2012)

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days
por: Merki-Feld, Gabriele S, et al.
Publicado: (2015)

The Efficacy of the Yasmin[Ethinylestradiol-Drospirenone (0.03/3 mg)] Treatment for Postoperative Abortion: A Protocol of Meta-Analysis
por: Tian, Tian, et al.
Publicado: (2022)

The effectiveness of 20 μg hepatitis B vaccine used for the prevention of HBV vertical transmission
por: Yonghao, Guo, et al.
Publicado: (2022)

Prognostic impact of troponin > 0.2 μg/ml and < 0.5 μg/m in UA/NSTIMI
por: Gomes de Sá, S, et al.
Publicado: (2003)

Microarrays for Microbes: the BμG@S Approach
por: Hinds, Jason, et al.
Publicado: (2002)

Ethinylestradiol/Chlormadinone Acetate: Dermatological Benefits
por: Guerra-Tapia, Aurora, et al.
Publicado: (2012)

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2011)

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
por: Bleecker, Eugene R, et al.
Publicado: (2011)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

Inhibitory effect of ethinylestradiol on coagulation factors in rats
por: Franco-Murillo, Yanira, et al.
Publicado: (2016)

Ethinylestradiol/Chlormadinone Acetate for Use in Dermatological Disorders
por: Vázquez, Mercedes Gómez, et al.
Publicado: (2012)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD
por: Feldman, Gregory, et al.
Publicado: (2016)

Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults
por: Nougarede, Nolwenn, et al.
Publicado: (2014)

Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

Comparison of the Effects of Hysteroscopic Cold Broad Sword Play Combined with Estrogen and Progestin Sequential Therapy and Drospirenone and Ethinylestradiol Tablets in Patients with Severe Intrauterine Adhesion
por: Zhou, Liping, et al.
Publicado: (2022)

Structure of the μ Opioid Receptor-G(i) Protein Complex
por: Koehl, Antoine, et al.
Publicado: (2018)

μECoG Recordings Through a Thinned Skull
por: Brodnick, Sarah K., et al.
Publicado: (2019)

Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study
por: Feldman, Gregory, et al.
Publicado: (2010)

BμG@Sbase—a Microarray Database and Analysis Tool
por: Witney, Adam A., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_rss5qvgrn0drmc1liogrti04ee